Comparative Pharmacology
Head-to-head clinical analysis: DIONOSIL OILY versus OXILAN 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIONOSIL OILY versus OXILAN 350.
DIONOSIL OILY vs OXILAN-350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DIONOSIL OILY is a radiographic contrast agent containing propyliodone, which is an iodine-containing compound that absorbs X-rays, thereby enhancing the visualization of body structures during imaging procedures.
Iodinated contrast medium that attenuates X-rays due to its iodine content, enhancing vascular and tissue contrast during imaging. It distributes in extracellular fluid and is freely filtered by glomeruli.
Adults: 10 mL intraurethral instillation as a sterile oily suspension (50% w/v) once daily for 3-5 days.
Intravenous: 0.5–2 mL/kg (350 mg I/mL) for CT imaging; maximum 200 mL total. Intra-arterial: 0.3–1.5 mL/kg per injection; maximum 200 mL per procedure.
None Documented
None Documented
Terminal elimination half-life of the iodine moiety is approximately 60 days due to slow release from fatty tissues. This long half-life reflects the persistence of the oily vehicle and slow deiodination, necessitating monitoring for cumulative iodine effects.
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 24 hours in severe impairment).
Primarily renal excretion of the water-soluble metabolite (propiodone) after hepatic deiodination; approximately 60-80% of the administered iodine is excreted in urine within 48 hours. Fecal excretion is negligible (<5%).
Renal: >90% unchanged drug within 24 hours; Biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent